financetom
Business
financetom
/
Business
/
$1.3 bln UK lawsuit accuses Amazon of misusing small sellers' data
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
$1.3 bln UK lawsuit accuses Amazon of misusing small sellers' data
Jun 6, 2024 8:15 AM

LONDON, June 6 (Reuters) - Amazon ( AMZN ) is facing a

one billion-pound ($1.3 billion) collective lawsuit from British

retailers who allege that the online marketplace misused their

data to boost its own market share and profits.

The British Independent Retailers Association (BIRA), an

umbrella body grouping numerous small traders, was due to file

the lawsuit on behalf of around 35,000 retailers at the

Competition Appeal Tribunal (CAT) in London on Thursday, its

lawyers said.

The suit alleges that Amazon ( AMZN ) made use of non-public data

provided by retailers selling goods on Amazon's ( AMZN ) Marketplace to

offer cheaper rival products for sale directly to consumers.

BIRA Chief Executive Andrew Goodacre said small

retailers had little choice but to use Amazon ( AMZN ), given its reach,

but that the case was intended to stop it putting them out of

business.

"The filing of the claim today is the first step towards

retailers obtaining compensation for what Amazon ( AMZN ) has done,"

Goodacre said in a statement.

Amazon ( AMZN ) did not immediately respond to a request for comment.

BIRA's case also alleges that Amazon ( AMZN ) manipulated the "Buy

Box" feature on its website, shown near the top of product

pages, to its own advantage.

The "Buy Box" is the subject of a separate lawsuit brought

on behalf of consumers and valued at up to 900 million pounds

($1.1 billion).

Britain's Competition and Markets Authority (CMA) said in

2022 that it was investigating Amazon ( AMZN ), including the way it

selects the products placed within the "Buy Box".

Last year, the CMA said it had accepted commitments from

Amazon ( AMZN ) to help protect fair competition on its retail platform.

($1 = 0.7830 pounds)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Market Chatter: Microsoft-Backed OpenAI, Bain Expand Partnership to Sell AI Tools to Bain Clients
Market Chatter: Microsoft-Backed OpenAI, Bain Expand Partnership to Sell AI Tools to Bain Clients
Oct 17, 2024
02:44 PM EDT, 10/17/2024 (MT Newswires) -- Microsoft ( MSFT )-backed (MSFT) OpenAI and Bain are extending their partnership to sell OpenAI's ChatGPT and other AI tools to the consulting firm's clients, The Wall Street Journal reported Thursday. The companies started a sales partnership in 2023 and in August 13,000 Bain consultants got licenses for ChatGPT Enterprise, according to the...
Sector Update: Consumer Stocks Flat to Higher Premarket Thursday
Sector Update: Consumer Stocks Flat to Higher Premarket Thursday
Oct 17, 2024
09:05 AM EDT, 10/17/2024 (MT Newswires) -- Consumer stocks were flat to higher premarket Thursday as the Consumer Staples Select Sector SPDR Fund ( XLP ) was inactive and the Consumer Discretionary Select Sector SPDR Fund ( XLY ) was 0.3% higher recently. Uber Technologies ( UBER ) is exploring a possible bid to acquire Expedia Group ( EXPE )...
Greenheart Gold Up 9.2% as it Completes a $36 Million Private Placement
Greenheart Gold Up 9.2% as it Completes a $36 Million Private Placement
Oct 17, 2024
02:31 PM EDT, 10/17/2024 (MT Newswires) -- Greenheart Gold ( GHRTF ) on Thursday said it closed a brokered private placement financing that raised $36 million as it placed 72.09-million shares priced at $0.50 each. Proceeds will be used to acquire properties mineral properties in Guyana and Suriname, for working capital and general corporate purposes. Greenheart Gold ( GHRTF )...
Kezar Life Sciences Gets Nod to Proceed With Autoimmune Hepatitis Trial; Ends Lupus Nephritis Study
Kezar Life Sciences Gets Nod to Proceed With Autoimmune Hepatitis Trial; Ends Lupus Nephritis Study
Oct 17, 2024
02:44 PM EDT, 10/17/2024 (MT Newswires) -- Kezar Life Sciences ( KZR ) said Thursday the Independent Data Monitoring Committee has recommended the Portola phase 2a trial of zetomipzomib in patients with autoimmune hepatitis to proceed without modification following its review. Kezar said the trial, which is being conducted in the US, has so far not shown any grade 4...
Copyright 2023-2026 - www.financetom.com All Rights Reserved